Department of Health and Social Care

John McDonnell Excerpts

Tuesday 30th June 2026 Commons Chamber

[John McDonnell (Hayes and Harlington) (Lab)]

The debate we have had so far highlights the issue at hand. This is an immense change to the way in which we will determine the delivery of drugs to the NHS, and one of my fears is that it will begin to weaken the existing controls. I think it politicises the process, because what will happen now is that Ministers will be able to determine the thresholds. In addition, I am concerned that decision making in the negotiations with the pharmaceutical companies has been transferred from NHS England to the Department itself. There will be real concerns that when we look for objective advice from NICE, the system that we have will now be politicised. I say to my hon. Friend on the Front Bench that it behoves the Government to ensure that we have a proper debate on this issue.

I welcome the comments that have just been made by my hon. Friend the Member for North Somerset (Sadik Al-Hassan), because I find them interesting, just as I have found the contributions from Members across the House. The costs have been set out today, and there is a vast range of figures. This could be resolved if the Government just published the impact study that we have all been asking for.

Members have emphasised that when No. 10 said very clearly that any additional costs would have to come from the NHS, we wanted to have a debate so that we could ask, “Where from? What areas of service will be reduced?”

[Peter Dowd (Bootle) (Lab)]

The NHS will carry out screening and evaluation of newborn babies for spinal muscular atrophy, or SMA, which causes spinal cord deterioration. It is a devastating genetic condition. The evaluation will start in October in England, but not in Northern Ireland or anywhere else. Does my hon. Friend agree that the will must be found to ensure comprehensive cover for all nations? We can have no more delays. We need action now to save the lives of children and prevent trauma for families.

[John McDonnell]

That is an incredibly relevant point in this debate. Many of us have examples of that, which is why we need to have a wider debate about the supply of drugs, their effectiveness and how they are evaluated. I thought we had a relatively objective system, but the deal throws that objectivity into question.

Figures on the scale of deaths have been bandied about. I want to hear the Government’s view and their proper analysis of that, because we have to engage with the reports from Karl Claxton, Andrew Hill and so forth, as others have mentioned.

The justification for the Trump deal was that it would increase UK exports to the US and increase overall investment in drugs in this country. I have yet to see any published evidence of that; in fact, the Government have not brought forward any evidence.

I also say to my hon. Friend the Minister, and this is political, that I remember the commitment given by the Prime Minister and the former Health Secretary that the NHS would not be on the table in any Trump deals. This deal does put it on the table, because it has consequences not just for the supply of drugs, but for investment in the NHS and decision making about what our constituents can access. It relates not only to what level of drugs they can access, but—if there are reductions in other expenditure—to whether they will get access to a GP or A&E, or get the care services for which we have been advocating for quite a while.

I thank the people who have been providing us with briefings on this issue, such as Global Justice Now and Just Treatment, which I have worked with over the years. They want to engage in the debate with the Government and to bring their expertise to the table, so I would welcome a commitment from the Minister to bring in those organisations before we move forward with implementation. This is my worry and that of those I have worked with: Kamran Abbasi, the editor of The British Medical Journal, has said that the deal

“will end up harming vulnerable people to boost the profits of already obscenely profitable drug companies.”

I do not want to support a deal that does that.